KMT2D-mediated H3K4me1 recruits YBX1 to facilitate triple-negative breast cancer progression through epigenetic activation of c-Myc

Bing Yao , Mengying Xing , Xiangwei Zeng , Ming Zhang , Que Zheng , Zhi Wang , Bo Peng , Shuang Qu , Lingyun Li , Yucui Jin , Haitao Li , Hongyan Yuan , Quan Zhao , Changyan Ma

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (7) : e1753

PDF
Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (7) : e1753 DOI: 10.1002/ctm2.1753
RESEARCH ARTICLE

KMT2D-mediated H3K4me1 recruits YBX1 to facilitate triple-negative breast cancer progression through epigenetic activation of c-Myc

Author information +
History +
PDF

Abstract

• YBX1 is a KMT2D-mediated H3K4me1-binding effector protein and mutation of YBX1 (E121A) disrupts its binding to H3K4me1.

• KMT2D and YBX1 cooperatively promote TNBC proliferation and metastasis by activating c-Myc and SENP1 expression in vitro and in vivo.

• YBX1 is colocalized with H3K4me1 in the c-Myc and SENP1 promoter regions in TNBC cells and increased YBX1 expression predicts a poor prognosis in breast cancer patients.

Keywords

histone H3 lysine 4 mono-methylation (H3K4me1) / lysine methyltransferase 2D (KMT2D) / triple-negative breast cancer (TNBC) / Y-box-binding protein 1 (YBX1)

Cite this article

Download citation ▾
Bing Yao,Mengying Xing,Xiangwei Zeng,Ming Zhang,Que Zheng,Zhi Wang,Bo Peng,Shuang Qu,Lingyun Li,Yucui Jin,Haitao Li,Hongyan Yuan,Quan Zhao,Changyan Ma. KMT2D-mediated H3K4me1 recruits YBX1 to facilitate triple-negative breast cancer progression through epigenetic activation of c-Myc. Clinical and Translational Medicine, 2024, 14(7): e1753 DOI:10.1002/ctm2.1753

登录浏览全文

4963

注册一个新账户 忘记密码

References

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

AI Summary AI Mindmap
PDF

173

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/